Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
FDA Approval
Sort By
Newest First
1 / 14
1 / 14
FDA Approval
Possible New Hope for Metastatic Cancer Patients: Food and Drug Administration Grants Approval for Clinical Trials For Lamassu's Groundbreaking Cancer Treatment Protocol
Lamassu Biotech
PR-M04-24-01
Apr 19, 2024
FDA New Drug Approvals
Many First-in-Class Drugs Approved by FDA in 2022, but Overall Approval Numbers Down
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-03-23-NI-03
Mar 07, 2023
Column: Clinical Trials
CAR-T Study Shines New Spotlight on Clinical Trials Representation
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-022--NI-06
Jul 02, 2022
Column: New Drug Watch
New Drug Watch: A Validation of the ‘Twincretin’ Approach to Type 2 Diabetes
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-022--NI-08
Jun 24, 2022
Column: New Drug Watch
Alzheimer Drug Still Controversial
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-03-022-NI-04
Mar 23, 2022
COVID-19 Vaccine
FDA Approves SPIKEVAX®, Moderna's mRNA COVID-19 Vaccine
Brand Institute
PR-M02-22-01
Feb 01, 2022
FDA Approval
FDA Grants Accelerated Approval for Aduhelm™ as the First and Only Alzheimer’s Disease Treatment to Address a Defining Pathology of the Disease
Biogen
PR-M06-21-015
Jun 08, 2021
FDA Approval
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
Bristol-Myers Squibb
PR-M06-21-008
Jun 07, 2021
FDA Approval
Novartis Cosentyx Receives FDA Approval for Treatment of Children and Adolescents with Moderate to Severe Plaque Psoriasis
Novartis
PR-M06-21-002
Jun 01, 2021
FDA Approval
Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer
Blueprint Medicines
PR-M11-20-027
Dec 02, 2020
Antibodies
Lilly's Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19
Eli Lilly and Company
PR-M11-20-023
Dec 01, 2020
FDA Approval
FDA Approves First Treatment for Ebola Virus
U.S. Food & Drug Administration
PR-M10-20-10
Oct 15, 2020
Opioid
Trevena Announces FDA Approval of OLINVYK Injection
Trevena
PR-M08-20-NI-30
Aug 18, 2020
FDA Approval
FDA Approves GSK’s BLENREP for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
GSK in Oncology
PR-M08-20-NI-11
Aug 06, 2020
COVID-19 Treatment
Common FDA-Approved Drug May Effectively Neutralize Virus That Causes COVID-19
Rensselaer Polytechnic Institute
PR-M07-20-NI-32
Jul 23, 2020
Nice Insight Overview
Drug Approval Trends: Significant Acceleration in Recent Years
Nigel Walker
Nice Insight
PAP-Q2-20-NI-001
Jul 01, 2020
FDA Approval
FDA Approves First-Of-Its-Kind Percep PC Neurostimulator with BrainSense Technology
Medtronic
PR-M06-20-NI-037-1471
Jun 26, 2020
FDA Approval
FDA Permits Marketing of First Game-Based Digital Therapeutic to Improve Attention Function in Children with ADHD
U.S. Food & Drug Administration
PR-M06-20-NI-021
Jun 16, 2020
FDA Approves GSK's Zejula
GSK
PR-M05-20-NI-014
May 08, 2020
FDA Approval
Novartis Announces FDA Approval of MET Inhibitor Tabrecta™ for Metastatic Non-Small Cell Lung Cancer with METex14
Novartis
PR-M05-20-NI-011-1570
May 07, 2020